Regeneron tops Q3 estimates, raises guidance and expands Sanofi deal
+13.33% to $927.89 from $818.77
What moved REGN
- Total revenue rose 36% year-over-year to about $5.1 billion, with GAAP diluted EPS of $18.45, also up 36%.
- Non-GAAP diluted EPS of $20.07 beat the roughly $16.48 analyst consensus by about 22%.
- Sanofi collaboration revenue rose 68% to $2.724 billion, while EYLEA HD U.S. sales rose 62% to $699 million.
- Regeneron raised its full-year 2026 guidance and expanded its Sanofi collaboration, which includes a $1.0 billion upfront payment to be recognized as collaboration revenue in the fourth quarter.
Sources: GuruFocus · Alphastreet · Benzinga · QuiverQuant